Compare IPW & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPW | VRAX |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 972.3K |
| IPO Year | 2021 | 2021 |
| Metric | IPW | VRAX |
|---|---|---|
| Price | $1.33 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 413.3K |
| Earning Date | 11-17-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,956,938.00 | N/A |
| Revenue This Year | $596.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.10 |
| 52 Week High | $2,019,375,000.00 | $13.19 |
| Indicator | IPW | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 25.36 | 22.68 |
| Support Level | $0.18 | $0.15 |
| Resistance Level | $1.57 | $3.01 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | 19.09 | 0.00 |
| Stochastic Oscillator | 36.22 | 15.95 |
iPower Inc is a technology-enabled commerce infrastructure company providing supply chain, logistics, fulfillment, warehousing and procurement solutions for e-commerce and distribution channels. Its product portfolio includes hydroponic products, gardening supplies, home goods and related accessories, with gardening and home products. Geographically, the company generates majority of its revenue from the United States, followed by Canada and other international markets.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.